Cory Simpson, MD, PhD, assistant professor of dermatology at the University of Washington, spoke to the need for more treatment options in genetic skin conditions and the possibility of drug ...

Krystal Biotech (KRYS) announced that on July 24, 2025, Japan’s Ministry of Health, Labour and Welfare, MHLW, granted marketing authorization to ...

The global dystrophic epidermolysis bullosa (DEB) market is expanding due to increased awareness, advanced diagnostics, and innovative treatments like Vyjuvek, a topical gene therapy by Krystal ...

A thrill-seeking Dubliner is gearing up for an 1,100km cycle from The Netherlands to Italy for an extremely good cause. […] ...

Introduction: Epidermolysis bullosa (EB), a group of autosomal heritable blistering diseases, is characterised by extensive phenotypic variability with considerable morbidity and mortality. EB is ...

Seventeen-year-old Brianna Ibarra from North Texas lives with epidermolysis bullosa, also known as "butterfly skin," a rare condition that causes her skin to blister or tear from even the slightest ...

Through painting, 17-year-old Brianna Ibarra is turning pain into purpose, raising thousands for Cook Children's Hospital.

Gaelic footballer Ellie Ward has a rare and painful genetic condition known as ‘butterfly skin’, but there is nothing ...

Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those living with rare and severe skin diseases, today announced the appointment of ...

- ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - ...

A CHEESE and wine evening in Painswick is raising funds for charity. The event, which is taking place at Catswood House, on Saturday, August 30, is in support of DEBRA, an organisation which helps ...

Krystal Biotech announced the first patient has been dosed in EMERALD-1, its phase 1/2 clinical trial evaluating KB801 for ...